Shweta Maniar is Director at RxSight, Inc. (RXST). They have made 1 open-market trade across 1 company since 2022, most recently 2026-06-17.
CIK 0001850826
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RXST | SELL · 10b5-1 | 2025-01-22 | 2025-01-27 | $30.87 | $217K | +4.4% | -9.9% | -54.7% |
| RXST | SELL · 10b5-1 | 2024-11-26 | 2024-11-26 | $45.88 | $347K | -14.4% | -24.4% | -36.8% |
| RXST | SELL · 10b5-1 | 2024-01-18 | 2024-01-19 | $45.72 | $585K | -2.2% | +19.9% | +11.2% |
| RXST | SELL · 10b5-1 | 2024-01-08 | 2024-01-09 | $45.00 | $289K | +2.9% | +6.3% | +22.3% |
| RXST | SELL · 10b5-1 | 2023-08-29 | 2023-08-29 | $28.06 | $241K | +4.8% | -2.0% | +4.7% |
| OFIX | SELL | 2023-03-10 | 2023-04-05 | $17.75 | $151K | +2.7% | +7.3% | +1.7% |
| SPNE | SELL · 10b5-1 | 2022-12-29 | 2022-12-30 | $8.00 | $30K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.